To ask the Secretary of State for Health and Social Care, what steps her Department is taking to offer support people with non-tuberculosis mycobacteria during winter 2022-23.
This answer is the replacement for a previous holding answer.
Answered on
28 November 2022
Patients with non-tuberculous mycobacteria will continue to be managed in primary and secondary care settings and treated with guideline based therapy, as recommended by the British Thoracic Society. The Society’s ‘Guideline for Long Term Macrolide Use’ suggests that those patients able to expectorate should be considered for testing for non-tuberculous mycobacteria prior to starting long term macrolide therapy.
Answered by
Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.